Moreover, when stratifying patients for their characteristics, they found that there was a difference in survival and, consequently, a higher response rate to erlotinib, when patients were non-smokers, when they had EGFR mutation type exon 19 and adenocarcinomas. Here, EGFR is linked to adenocarcinoma.